Serum Levels of the Adipokine FGF21 Depend on Renal Function

  1. Sebastian Stein, MS1,
  2. Anette Bachmann, MD1,
  3. Ulrike Lössner1,
  4. Jürgen Kratzsch, PHD2,
  5. Matthias Blüher, MD1,
  6. Michael Stumvoll, MD1 and
  7. Mathias Fasshauer, MD13
  1. 1University of Leipzig, Department of Internal Medicine III, Leipzig, Germany
  2. 2University of Leipzig, Institute of Laboratory Medicine, Leipzig, Germany
  3. 3Interdisciplinary Center for Clinical Research (IZKF) Leipzig, Leipzig, Germany
  1. Corresponding author: Mathias Fasshauer, mathias.fasshauer{at}medizin.uni-leipzig.de

Abstract

OBJECTIVE—To investigate renal elimination of the adipokine fibroblast growth factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as compared with control subjects with a glomerular filtration rate (GFR) >50 ml/min.

RESEARCH DESIGN AND METHODS—FGF21 was determined by enzyme-linked immunosorbent assay in control (n = 60) and CD (n = 60) patients and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, and inflammation in both groups.

RESULTS—Median serum FGF21 levels were >15-fold higher in CD patients (3,710.6 ng/l) than in subjects with a GFR >50 ml/min (201.9 ng/l) (P < 0.001). Furthermore, serum creatinine positively and GFR negatively predicted FGF21 concentrations in multiple regression analyses in control subjects (P < 0.05).

CONCLUSIONS—FGF21 serum levels increase in CD patients and are related to markers of renal function in control subjects.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 7 October 2008.

    S.S. and A.B. contributed equally to this work.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted September 24, 2008.
    • Received June 10, 2008.
« Previous | Next Article »Table of Contents

This Article

  1. Published online before print October 7, 2008, doi: 10.2337/dc08-1054 Diabetes Care January 2009 vol. 32 no. 1 126-128
  1. » Abstract
  2. Full Text
  3. Full Text (PDF)
  4. All Versions of this Article:
    1. dc08-1054v1
    2. 32/1/126 most recent

Current Issue

  1. February 2010, 33 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care